Literature DB >> 23178160

Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2.

María C Diaz Flaqué1, Rocío Vicario, Cecilia J Proietti, Franco Izzo, Roxana Schillaci, Patricia V Elizalde.   

Abstract

Cell cycle regulator p21(CIP1) has controversial biological effects in breast cancer since in spite of its role as cell cycle inhibitor and promoter of cellular senescence, it also induces cell proliferation and chemoteraphy resistance. We here explored the molecular mechanisms involved in progestin regulation of p21(CIP1) expression. We also investigated the biological effects of p21(CIP1) in breast cancer cells. We found that the synthetic progestin medroxyprogesterone acetate (MPA) upregulates p21(CIP1) protein expression via c-Src, signal transducer and activator of transcription 3 (Stat3) and ErbB-2 phosphorylation. Notably, we also found that ErbB-2 nuclear function plays a key role in MPA-induction of p21(CIP1) expression. Interestingly, we determined that progestin drives p21(CIP1) transcriptional activation via a novel nonclassical transcriptional mechanism in which progesterone receptor is recruited along with Stat3 and ErbB-2 to a Stat3 binding site at p21(CIP1) promoter. Our findings revealed that ErbB-2 functions as a coactivator of Stat3 in progestin induction of p21(CIP1) transcriptional activation. Furthermore, we demonstrated that blockage of p21(CIP1) expression strongly inhibited in vitro and in vivo progestin-induced breast cancer cell proliferation. These results further support the hypothesis that according to cell context and type of stimulus, p21(CIP1) is capable of inducing cell cycle progression. Moreover, we provided evidence that Stat3 and nuclear ErbB-2 are key players in progestin-induced p21(CIP1) regulation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178160     DOI: 10.1016/j.steroids.2012.11.003

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  12 in total

1.  Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor.

Authors:  Maria Loreto Bravo; Mauricio P Pinto; Ibeth Gonzalez; Barbara Oliva; Sumie Kato; Mauricio A Cuello; Carol A Lange; Gareth I Owen
Journal:  Endocrine       Date:  2014-05-23       Impact factor: 3.633

Review 2.  Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.

Authors:  Katherine A Leehy; Thu H Truong; Laura J Mauro; Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2017-04-23       Impact factor: 4.292

Review 3.  Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Authors:  Rosalía I Cordo Russo; María F Chervo; Santiago Madera; Eduardo H Charreau; Patricia V Elizalde
Journal:  Horm Cancer       Date:  2019-01-17       Impact factor: 3.869

4.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Authors:  L Venturutti; L V Romero; A J Urtreger; M F Chervo; R I Cordo Russo; M F Mercogliano; G Inurrigarro; M G Pereyra; C J Proietti; F Izzo; M C Díaz Flaqué; V Sundblad; J C Roa; P Guzmán; E D Bal de Kier Joffé; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

5.  Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.

Authors:  Cecilia J Proietti; Franco Izzo; María Celeste Díaz Flaqué; Rosalía Cordo Russo; Leandro Venturutti; María Florencia Mercogliano; Mara De Martino; Viviana Pineda; Sergio Muñoz; Pablo Guzmán; Juan C Roa; Roxana Schillaci; Patricia V Elizalde
Journal:  Mol Endocrinol       Date:  2015-09-04

6.  Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance.

Authors:  Chang-Yuan Wei; Qi-Xing Tan; Xiao Zhu; Qing-Hong Qin; Fei-Bai Zhu; Qin-Guo Mo; Wei-Ping Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

7.  Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth.

Authors:  María F Chervo; Rosalía I Cordo Russo; Ezequiel Petrillo; Franco Izzo; Mara De Martino; Nicolás Bellora; Mauro E Cenciarini; Violeta A Chiauzzi; Lucía Santa María de la Parra; Matías G Pereyra; Leandro N Güttlein; Osvaldo L Podhajcer; José L Daniotti; Agustina Dupont; Sabrina Barchuk; Silvina Figurelli; Daniel Lopez Della Vecchia; Juan C Roa; Pablo Guzmán; Cecilia J Proietti; Roxana Schillaci; Patricia V Elizalde
Journal:  Oncogene       Date:  2020-08-25       Impact factor: 9.867

8.  Analysis of HER2 genomic binding in breast cancer cells identifies a global role in direct gene regulation.

Authors:  Aisling M Redmond; Soleilmane Omarjee; Igor Chernukhin; Muriel Le Romancer; Jason S Carroll
Journal:  PLoS One       Date:  2019-11-20       Impact factor: 3.240

9.  Nuclear ErbB2 represses DEPTOR transcription to inhibit autophagy in breast cancer cells.

Authors:  Yanli Bi; Longyuan Gong; Pengyuan Liu; Xiufang Xiong; Yongchao Zhao
Journal:  Cell Death Dis       Date:  2021-04-14       Impact factor: 8.469

Review 10.  Molecular determinants of context-dependent progesterone receptor action in breast cancer.

Authors:  Christy R Hagan; Carol A Lange
Journal:  BMC Med       Date:  2014-02-20       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.